DrugsControl Media Services
DrugsControl.org

News Detail

Boehringer Ingelheim offers Humira biosimilar at 92% discount (20-07-2024)

Washington, 20 July 2024: Boehringer Ingelheim will sell an unbranded version of AbbVie's reference drug at a 92% discount to gain traction in the Humira (adalimumab) biosimilar market.

Patients will be able to purchase adalimumab-adbm exclusively through GoodRx, an on......
View Details

Source : Pharmaceutical Technolgy
Boehringer Ingelheim unbranded version of AbbVie's reference drug Humira (adalimumab) biosimilar

Related News